---
schema_version: "secwatch.filing_event.v1"
accession: "0001171843-25-002401"
form_type: "8-K"
ticker: "ABUS"
cik: "0001447028"
company_name: "Arbutus Biopharma Corp"
filed_at: "2025-04-23T23:59:59+00:00"
generated_at: "2026-05-23T07:59:07.651744+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.55
calibrated_materiality_score: 0.55
confidence: "high"
source: SEC EDGAR
---

# Arbutus announces five abstracts on imdusiran and AB-101 accepted at EASL 2025, including late-breaker

## Summary
- Five abstracts accepted for poster presentation at EASL Congress 2025 (May 7-10, Amsterdam); one late-breaker (LB25153).
- Abstract 1768: IM-PROVE I study shows HBsAg at baseline and NA discontinuation associated with functional cure in CHB subjects.
- Abstract 2043: Rapid HBV RNA decline during imdusiran lead-in, then transient increases with interferon, linked to HBsAg seroclearance.
- AB-101 (oral PD-L1 inhibitor) data: well-tolerated in healthy/subjects, dose-responsive PD-L1 RO, high liver biodistribution.
- Late-breaker LB25153: off-treatment antiviral efficacy and safety of repeat imdusiran + VTP-300 with/without nivolumab in CHB.

## SEC filing metadata
- accession: 0001171843-25-002401
- form_type: 8-K
- ticker: ABUS
- cik: 0001447028
- company_name: Arbutus Biopharma Corp
- filed_at: 2025-04-23T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.55
- calibrated_materiality_score: 0.55
- confidence: high
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1447028/000117184325002401/0001171843-25-002401-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1447028/000117184325002401/f8k_042325.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001171843-25-002401
- JSON: https://secwatch.observer/filing/0001171843-25-002401.json
- Plain text: https://secwatch.observer/filing/0001171843-25-002401.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.